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Summary &horbar; This cross-over trial involving 6 Blue Belgian double-muscled calves aimed to investigate
whether ipratropium bromide inhaled alone or in combination with clenbuterol hydrochloride could
prevent the dramatic clinical and pulmonary disturbances that are observed during an experimentally
induced bronchoconstriction. Inhaled bronchodilators significantly influenced the clinical and func-
tional responses of bovines subjected to a 5-hydroxytryptamine perfusion. However, despite a mean
(standard error) wash-out period of 11.2 (3.1) and 7.5 (0.9) d after the 1 st and the 2nd one-day chal-
lenges, respectively, first-order carry-over effects (ie those remaining from the previous treatment), effects
of the period during which the treatment was allocated and interaction effects did not allow a definitive
interpretation of overall treatment differences.
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Résumé &horbar; Aptitude des bronchodilatateurs à prévenir un syndrome de détresse respiratoire expé-
rimentale chez le bovin. Six veaux hyperviandeux de race Blanc Bleu Belge ont été introduits dans cette
étude dont le but fut de déterminer si le bromure d’ipratropium, inhalé seul ou en association avec de
l’hydrochlorure de clenbutérol, permet de prévenir les perturbations cliniques et fonctionnelles observées
lors d’une bronchoconstriction expérimentale. Les bronchodilatateurs influencèrent, de manière signi-
ficative, la réponse clinique et fonctionnelle des bovins soumis à une perfusion lente de 5-hydroxy-
tryptamine. Néanmoins, malgré un intervalle d’attente moyen (erreur standard) de 11,2 (3,1 j et 7,5 
[0,9J j respectivement après le premier et le deuxième traitement, des interactions, des effets transfé-
rés du traitement précédent et des effets de la période durant laquelle le traitement fut administré n’ont
pas permis une interprétation définitive des différences thérapeutiques globales observées.
aérosol / bronchodilatateur / cienbutéroi / inhalation / ipratropium
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INTRODUCTION
Due to the morphological and functional
peculiarities of their lungs, cattle are prone
to develop rapid respiratory failure (Lekeux
ef al, 1984). Deaths, reduced weight gains,
additional labour and veterinary costs all
contribute to the financial loss that is due
to respiratory disease in calves. In the UK,
such losses exceed £50 million annually
(Gourlay etal, 1989).
In Belgium, acute respiratory distress syn-
drome is a common and dramatic syndrome
in which the bovine respiratory syncytial virus
(Wellemans and Leunen, 1975) plays an
important role. Several studies concerning
the pathogenesis and the physiological
changes associated with the bovine respi-
ratory syncytial virus have been undertaken
(Lekeux ef al, 1985; Kimman et al, 1989a,b;
Leblanc etal,1991) and have shown that the
syndrome can be associated with airway
obstruction (Lekeux et al, 1985) and hyper-
reactivity (Leblanc ef al, 1991 ). Conse-
quently, an aerosol delivery equipment suit-
able for calves has been designed. Several
studies have been dedicated to the perfor-
mances of this aerosol delivery equipment
and to the physical properties of therapeutic
droplets atomized by means of this equip-
ment (Genicot et al, 1994a,b).
On the basis of this background, the pre-
sent study aimed to investigate whether
ipratropium bromide inhaled alone or in com-
bination with clenbuterol hydrochloride was
able to prevent the dramatic clinical and pul-
monary disturbances that are observed dur-




Six Blue Belgian double-muscled calves with a
mean (se, standard error) bodyweight of 112.0
(2.9) kg were involved in this cross-over trial which
lasted 32 d. The animals were randomly allocated
to a treatment (A, B or C) sequence (table I). A
mean (se) wash-out period of 11.2 (3.1) and 7.5
(0.9) d was introduced after the 1 st and the 2nd
one-day challenge, respectively.
Examination under normal breathing (NB) con-
ditions was performed 7.5 (1.6) d after the 3rd
challenge.
Treatments
As described in table II, bronchodilators (treat-
ments BC-A and BC-B) and saline (treatment
BC-C) were atomized into the calves’ tidal vol-
ume. After a 1 h resting period, a continuous intra-
venous administration (0.015 mg.kg-.min active
base) of a 5-hydroxytryptamine creatinine sulfate
(Sigma Chemical Co, Saint Louis, MO, USA)
solution began in the 3 groups. This administra-
tion was performed by means of a perfusion pump
(960 Volumetric Infusion Pump, Imed Ltd, San
Diego, CA, USA). The main effects of this inflam-
matory mediator are an intense tachypnea, a dif-
fuse bronchoconstriction and a pulmonary arterial
hypertension (Desmecht et al, 1992).
After the sequence of treatments, each ani-
mal was submitted to a further treatment (NB)
which was undertaken in order to test the influ-
ence of the experimental conditions on the res-
piratory pattern. During NB, neither inhalant nor
bronchoconstrictor was administered.
Pulmonary function tests
Throughout this study, pulmonary function tests
using the monofrequency forced oscillation
method (Reinhold etal, 1992; Close etal, 1994)
were carried out. A compact portable device (LF1,
Ganshorn, Medizin Electronic GmbH, Germany)
was used to measure the oscillatory resistance
(Ros) and the phase angle (T) while the animals
were in a quiet state and wearing a snugly fitting
face mask which had been checked for its air-
tightness and dead space. The Ros and 4’ val-
ues made it possible to split the impedance of
the respiratory system (Z,S) into its real (Re) and
imaginary (1m) components. The respiratory sys-
tem compliance (Crs) was calculated from the Im
value (Close et al, 1994).
Timetable for collection of clinical
and pulmonary function data
During treatments BC-A, BC-B and BC-C, the
respiratory rate was determined and a pulmonary
function test was performed before (time 0) the
inhalation of therapy A, B or C and at the 5th
(time 5) and the 24th (time 24) min of the 5-
hydroxytryptamine challenge which lasted 26.1 1
(0.5) min.
During the treatment (NB), which was con-
ducted with calves that were breathing normally,
the respiratory rates and pulmonary function
parameters were collected twice at a 24 min inter-
val, ie at 0 and 24 min, respectively.
Data analysis
For each animal, the relative changes observed
in respiratory rates and pulmonary function
parameters were expressed as a percentage of
their baseline value. All these changes (A) were
assessed using a small sample inferential pro-
cedure (Mendenhall and Reinmuth, 1978), ie a
2-tailed Student’s ttesting the null hypothesis A =
0% against the alternative that is either greater
than or less than 0%.
In order to compare the protective properties
of substances atomized in the tidal volume of
calves, a crude overall within-animal comparison
(Pocock, 1984) of substances was done on the
respiratory rate and the pulmonary function
parameters. A 1-tailed ttest for paired differences
was used to assess whether the mean differ-
ences as large as those observed had a reason-
able chance of occurring even if the substances
were equally effective (Pocock, 1984). This rela-
tively straightforward analysis makes the 3 fol-
lowing main assumptions: no period effect, no
treatment-period interaction, and no carry-over
effect. Consequently, these 3 assumptions were
checked as described in Jones and Kenward
(1989). This check was especially important in
the detection of period and treatment effects,
interactions and first-order carry-over effects, ie
those remaining from the previous treatment.
The significance of differences was accepted
at P 5 0.05. The results are presented as mean
(se). When several P-values are required to
express the degree of significant changes
observed in more than 2 groups or at the 2 dif-




The mean respiratory rates collected during
the 4 treatments are displayed in table III.
The period during which the treatment was
allocated, the actual and previous treatments
all significantly influenced the responses.
Treatment B led to a significantly better pro-
tection against tachypnea when the previ-
ous treatment had not included any bron-
chodilator.
The results from the crude analysis were
as follows. Under the normal experimental
conditions (NB), ie neither inhalant nor bron-
choconstrictor administered, the respiratory
rate did not significantly change (P= 0.8194)
over time. However, under treatments BC-A,
BC-B and BC-C, ie when 1 of the 3
inhalants and the bronchoconstrictor were
administered, a significant (0.0002 < P <
0.0342) increase in the respiratory rate was
observed at both times 5 and 24. This was
especially true (0.0002 5 P < 0.0013) during
treatment BC-C. In treatment BC-C, the res-
piratory rates collected during the 5-hydrox-
ytryptamine perfusion reached 282.1 %
(22.0%) of their baseline values. After pre-
treatments A and B, this percentage reached
207.5% (18.7%) during the perfusion.
At time 24, the relative longitudinal
changes observed in respiratory rates of
each animal under treatments B and C,
were significantly greater (P = 0.0053 and
0.0004, respectively) than those observed
under treatment NB. Furthermore, the rela-
tive respiratory rates observed at time 24
under pretreatment A were significantly
greater (P = 0.0374) than those observed
under treatment NB. When comparing the
enhancement of the respiratory rates
observed (at times 5 and 24) under treat-
ments BC-A and BC-B, no significant (P= =
0.2887 at time 5 and P = 0.4078 at time 24)
difference was detected. Under treatment
BC-B, the observed relative enhancement
in the respiratory rate was significantly (P= =
0.0275 at time 5 and P = 0.0389 at time 24)
lower than that observed under treatment
BC-C. Under treatments BC-A and BC-C,
the observed relative enhancement was not
significantly different.
Functional parameters
The Ros and Crs values are presented in
table III. For both parameters, interactions
between actual and previous treatments,
between a treatment and the period during
which it was administered were detected.
R.s
In the crude analysis, the major increase
(0.0016 < P <_ 0.0043) in the Ros values was
detected in pretreatment C. During treat-
ments BC-A and NB, Ros did not (0.0938
5 P5 0.2588) significantly change over time.
In treatment BC-B, a significant enhance-
ment of the Ros values was detected (P =
0.0257) at time 5. Values collected at time
24 showed that the rises in the Ros values
observed in treatments BC-A, BC-B and
BC-C were significantly greater (P= 0.0232,
0.0156 and 0.0009, respectively) than those
in treatment NB. In treatments BC-A and
BC-B, the Ros enhancement percentages
were not (0.3126 <- P <- 0.323) significantly
different. Compared to the relative Ros
enhancement observed in treatment BC-C,
those observed during treatments BC-A
and BC-B were significantly (0.0085 sP s
0.0262) lower. In treatment BC-C, Ros
indeed reached 161.4% (10.4%) of its base-
line value whereas it reached 121.9% (4.5%)
in treatments BC-A and BC-B.
Crs
The following results are also from the crude
analysis. When the calves were submitted to
treatment NB, no significant change was
detected in the Cr, values. However, in treat-
ments BC-A, BC-B and BC-C, a signifi-
cant (0.0022 s Ps 0.0438) decrease in the
Crs values was observed at times 5 and 24.
This was especially true (0.0022 < P <
0.0048) for treatment BC-C.
The relative longitudinal decline observed
in the Crs values during treatment NB was
significantly lower than that observed in
treatments BC-A (P = 0.0043), BC-B (P= =
0.0019) and BC-C (P = 0.0001). In treat-
ments BC-A and BC-B, the relative
decreases in the Crs values were not sig-
nificantly different (0.0924 s P <_ 0.1326).
The same observation was made (0.0601
< P <_ 0.1046) when comparing the relative
changes in Crs values observed in treat-
ments BC-B and BC-C. However, the rel-
ative decline in Crs values observed in treat-
ment BC-A was significantly (P = 0.0109
at time 5 and P 0.0183 at time 24) lower
than that observed in treatment BC-C. In
treatment BC-C, during the 5-hydroxy-
tryptamine perfusion, Crs dropped to 69.4%
(2.7%) of its baseline values. In treatments
BC-A and BC-B, that parameter fell to
81.2% (2.8%) of its baseline values.
DISCUSSION
The results obtained during treatment NB
convincingly support the fact that the experi-
mental conditions did not influence the res-
piratory pattern.
The present study did not generate data
suggesting that 0.9% saline does not induce
a bronchoconstriction in healthy animals.
However, it seems unlikely that 0.9% saline
may induce such a phenomenon. Indeed,
in a previous study (Genicot et al, 1994c),
0.9% saline, which was administered to
calves suffering from a natural acute respi-
ratory distress syndrome, did not signifi-
cantly influence the pulmonary function
parameters.
The observed lower hyperpnea in ani-
mals pre-treated with bronchodilator(s) might
be the result of a lower hypoxemia due to a
lower diffuse bronchoconstriction. The fact
that the pulmonary 5HT-induced changes
were reduced by bronchodilators is in accor-
dance with other studies. Indeed, atropine
partially inhibits the respiratory effects of
5-HT in calves (Linden et al, 1993), dogs
(Islam et al, 1974; Krell and Chakrin, 1976)
and rats (Church, 1975). Moreover, P2-
adrenoreceptor stimulants have been shown
to relax airway smooth muscles irrespective
of whether they have been contracted by
different potential asthma mediators such
as carbachol, histamine, 5-HT, PGF2cr., or
substance P (Persson and Carlsson, 1987).
Effects due to the period during which
the treatment was allocated, first-order carry-
over and interaction were detected in this
cross-over trial. These effects made it some-
what difficult to interpret overall treatment
differences within patients. There is no bio-
logical explanation as yet for the detected
first-order carry-over effects, ie those
remaining from the previous challenge.
Although indirect components could have
modulated serotonin-induced bronchocon-
striction through the formation of cyclooxy-
genase products (Bakhle and Smith, 1977;
Mitchell and Adcock, 1988) and activation of
(3-adrenergic receptors (Innes, 1962;
Pluchino, 1972; Freeman ef al, 1981 resid-
ual effects from the inhaled solution(s)
and/or from the 5-hydroxytryptamine perfu-
sion seem unlikely. The following explana-
tions may be advanced. During this experi-
ment, the challenges were separated by a
washout period of at least 6 d, during which
time the subjects did not receive any med-
ication. Tachyphylaxis to R2-agonists is a
well-known phenomenon both in vitro and in
vivo (Conolly et al, 1987; Svedmyr and L6f-
dahl, 1987; Vathenen et al, 1988) but there
is no convincing evidence for the develop-
ment of a clinically significant tachyphylaxis
of antiasthmatic effects (Larsson et al, 1977;
Svedmyr and L6fdahl, 1987; Svedmyr,
1990). Moreover, in the present study, the
calves were not exposed to more than 1
inhalation of !2-agonist. In addition, the dis-
sociation half-lives (mean ± SD) of 3H-ipra-
tropium iodide are 6.6 ± 0.3 min, 2.1 ± 0.3
min and 15.5 ± 1.2 min for Hm1, Hm2 and
Hm3-receptors, respectively (Disse et al,
1992; Speck and Hammer, 1993).
A long-term tolerance (a tolerance last-
ing several days) to repeated 5-hydroxy-
tryptamine challenges has not been inves-
tigated before. In addition, the literature
concerning the short-term tolerance to 5-
hydroxytryptamine seems controversial,
indicating either the existence (Buckner et
al, 1991) or the absence (Colebatch et al,
1966) of such a tolerance. Despite this con-
troversy, it is interesting to note that the
clinical and functional parameters returned
to baseline within 20 min after the end of
a 5 min challenge with intravenously admin-
istered 5-hydroxytryptamine (Desmecht et
al, 1992). Moreover, administration of 5-
hydroxytryptamine results in minimal pul-
monary oedema. Even lethal doses of 5-
hydroxytryptamine produced only patchy
pulmonary congestion (Aitken and Sanford,
1972). Finally, although methacholine is a
cholinergic agonist, its repeated adminis-
tration induces a short-term tolerance when
more than 1 treatment is made within a 24 h
period. This tolerance is reversible within
a period of several hours (Beckett et al,
1992).
In conclusion, inhaled bronchodilators
significantly influenced clinical and func-
tional responses of animals subjected to a
5-hydroxytryptamine challenge. However,
first-order carry-over effects, effects of the
period during which the treatment was allo-
cated and interaction effects did not permit
a clear interpretation of the overall treat-
ment differences within animals.
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